Eldelumab [anti-interferon-γ-inducible protein-10 antibody] induction therapy for active Crohn's disease: A randomised, double-blind, placebo-controlled phase IIa study
- William J. Sandborn
- , Paul Rutgeerts
- , Jean Frédéric Colombel
- , Subrata Ghosh
- , Robert Petryka
- , Bruce E. Sands
- , Pranab Mitra
- , Allison Luo
Research output: Contribution to journal › Article › peer-review